Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 11/20 | 0.52 |
| ▸ | POLR1A | O95602 | 1/20 | 0.50 |
| ▸ | PREP | P48147 | 2/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895679 | 0.77 | KMT2A (0.56) | KMT2A | |
| SCHEMBL27628255 | 0.77 | PRKCZ (0.63) | — | |
| SCHEMBL4979910 | 0.75 | ROCK2 (0.56) | KCNH2KMT2A | |
| SCHEMBL3955552 | 0.75 | ALDH1A1 (0.62) | DRD4KMT2A | |
| SCHEMBL30365687 | 0.75 | ALDH1A1 (0.62) | DRD4KMT2A | |
| SCHEMBL20477092 | 0.73 | TAS1R3 (0.56) | DRD4KMT2A | |
| SCHEMBL30287961 | 0.73 | POLR1A (0.47) | POLR1AKCNH2KMT2A | |
| SCHEMBL17255044 | 0.73 | POLR1A (0.47) | POLR1AKCNH2KMT2A | |
| SCHEMBL3329899 | 0.72 | NPC1 (0.70) | KMT2A | |
| SCHEMBL20180732 | 0.72 | CYP3A4 (0.50) | PREPDPP7KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978751-B1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-12-05 | — | — | EP | disclosed |
| US-9738655-B2 | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160145263-A1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-05-26 | — | — | US | disclosed |
| EP-2978751-A1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-02-03 | — | — | EP | disclosed |
| WO-2014160668-A1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160145263-A1 | TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS | TFPI2, TFPI, F12 | DRD4 4615/4885POLR1A 4419/4885PREP 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.